is isn an aquistion target at this level?

Yesterday GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) announced that RELVAR® ELLIPTA®, a once daily treatment for asthma and COPD, had recieved EU marketing clearance.

In the same announcement it mentions that its use is not suitable for everyone, condition and its use needs monitoring.

Further, Darrell Baker, SVP & Head, GSK Global Respiratory Franchise, said, “For many years GSK has been focused on developing a portfolio of new treatments for patients across the world with asthma and COPD.”

Which made me think, at this price does ISN become very attractive to GSK and/or THRX??